Novel Targeted Agents and Immunotherapy in Breast Cancer.

Authors
Category Primary study
JournalAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Year 2017
The treatment of breast cancer is generally determined according to breast cancer subtype: hormone receptor-positive (luminal), triple-negative (basal-like), and HER2-overexpressing breast cancer. Recent years have seen the development of exciting novel and potent therapeutics based on molecular pathways, immune modulation, and antibody conjugates. In this article, we cover new and emerging therapeutic areas and ongoing clinical trials that may result in further improvements in breast cancer outcomes.
Epistemonikos ID: 8a5ca95ac9a336771b3681227ccaebf3ac349a77
First added on: Jan 10, 2022